AUTHOR=Yi Jianing , Yi Pingyong , Wang Wei , Wang Huan , Wang Xinyu , Luo Hanjia , Fan Peizhi 

TITLE=A Multicenter Retrospective Study of 58 Patients With Primary Thyroid Diffuse Large B Cell Lymphoma

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 11 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00542

DOI=10.3389/fendo.2020.00542

ISSN=1664-2392

ABSTRACT=BACKGROUND: Primary thyroid diffuse large B cell lymphoma (DLBCL) is a rare type of extranodal lymphoma, optimal treatment methods and the key prognostic factors have not been established. 
METHODS: The clinical data of 58 patients with primary thyroid DLBCL from January 2007 to December 2017 were collected. Kaplan–Meier method and log-rank tests were used for the survival analysis. The Cox regression analysis was performed to evaluate the prognostic factors.
RESULTS: The follow-up time was 6–120 months, 5-year Overall survival (OS) and Progression Free Survival (PFS) were 73% and 61% respectively. Single factor analysis showed that IPI, Ki-67, treatment modalities, Hans classification, Myc/Bcl-2 protein coexpression and administration of rituximab had significant effect on the 5-year OS and PFS (P<0.05); while age, sex, Bcl-2 protein expression, Myc protein expression, tumor stage, tumor size, Hashimoto’s thyroiditis and B symptoms were not associated with prognosis (P>0.05). multivariate risk regression analysis revealed that Myc/Bcl-2 protein coexpression, treatment modalities, and Rituximab were independent prognostic factors (P<0.05). 
CONCLUSIONS: Patients with primary thyroid DLBCL who received combination chemotherapy with Radiotherapy had a better prognosis. Surgical treatment alone was not associated with the prognosis and is used only for diagnosis. Rituximab could improve the survival time of patients.